Novel therapies in asthma: Leukotriene antagonists, biologic agents, and beyond

American Journal of Therapeutics

Volumn 20, Issue 1, 2013, Pages 79-103

  Papierniak, Eric S ^a   Lowenthal, David T ^a   Harman, Eloise ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

asthma; bronchial thermoplasty; leukotriene antagonists; montelukast; omalizumab; zafirlukast

Indexed keywords

ALTRAKINCEPT; ANRUKINZUMAB; BECLOMETASONE; BIOLOGICAL PRODUCT; BUDESONIDE; CROMOGLYCATE DISODIUM; DACLIZUMAB; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEBRIKIZUMAB; LEUKOTRIENE RECEPTOR AFFECTING AGENT; MOMETASONE FUROATE; MONTELUKAST; OMALIZUMAB; PASCOLIZUMAB; PIOGLITAZONE; PITRAKINRA; PLACEBO; PREDNISONE; ROSIGLITAZONE; SALBUTAMOL; SALMETEROL; TRALOKINUMAB; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; WARFARIN; ZAFIRLUKAST; ZILEUTON;

ALLERGIC ASTHMA; ALLOPATHY; ANAPHYLAXIS; ANTIGEN SPECIFICITY; ARTICLE; ASTHMA; BIOCHEMISTRY; BRONCHOSPASM; CHRONIC OBS; CHRONIC OBST; CHRONIC OBSTR; CHURG STRAUSS SYNDROME; COMORBIDITY; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; ENDOSCOPIC THERAPY; FOLLOW UP; HUMAN; INJECTION SITE REACTION; LIVER FAILURE; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LUNG FUNCTION; MONOTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROTHROMBIN TIME; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL SIGNIFICANCE; SUICIDE; TRANSPLANT RE; TREATMENT RESPONSE;

ABLATION TECHNIQUES; ALGORITHMS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BRONCHOSCOPY; DECISION SUPPORT TECHNIQUES; DRUG APPROVAL; HUMANS; LEUKOTRIENE ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84872895158     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31826915c2     Document Type: Article

References (243)

1. Chu EK, Drazen JM. Asthma: One hundred years of treatment and onward. Am J Respir Crit Care Med. 2005;171:1202-1208 (Pubitemid 40740726)
2. Kazani S, Israel E. Update in asthma 2010. Am J Respir Crit Care Med. 2011;184:291-296
3. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181:315-323
4. Sanders M. Inhalation therapy: An historical review. Prim Care Respir J. 2007;16:71-81 (Pubitemid 46698770)
5. GINA. From the global strategy for asthma management and prevention, global initiative for asthma (GINA) 2010. Available from: Http://www.ginasthma. org/. Accessed November 30, 2011
6. Program, NAEAP. Expert panel report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94-S138
7. Marketos SG, Ballas CN. Bronchial asthma in themedical literature of Greek antiquity. J Asthma. 1982;19:263-269 (Pubitemid 13180816)
8. Homer, Fagles R, Knox B. The Iliad. New York, NY: Viking; 1990:683
9. Holgate ST. A brief history of asthma and its mechanisms to modern concepts of disease pathogenesis. Allergy Asthma Immunol Res. 2010;2:165-171
10. Moorman JE, Zahran H, Truman BI, et al. Current asthma prevalence - United states, 2006-2008. MMWR Surveill Summ. 2011;60(Suppl):84-86
11. Sullivan PW, Ghushchyan VH, Slejko JF, et al. The burden of adult asthma in the United States: Evidence from the Medical Expenditure Panel Survey. J Allergy Clin Immunol. 2011;127:363-369. e1-e3
12. Graham LM. Classifying asthma-. Chest. 2006. 130(1 Suppl):13S-20S. (Pubitemid 44107232)
13. Taylor DR, Bateman ED, Boulet L-P, et al. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008;32:545-554
14. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol. 1996;98(6 pt 1): 1016-1018 (Pubitemid 27014791)
15. Chapman KR, Barnes NC, Greening AP, et al. Single maintenance and reliever therapy (SMART) of asthma: A critical appraisal. Thorax. 2010;65:747-752
16. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26 (Pubitemid 43265239)
17. Liao MM, Ginde AA, Clark S, et al. Salmeterol use and risk of hospitalization among emergency department patients with acute asthma. Ann Allergy Asthma Immunol. 2010;104:478-484
18. Salpeter SR, Buckley NS, Ormiston TM, et al. Metaanalysis: Effect of long-Acting beta-Agonists on severe asthma exacerbations and asthma-related deaths. Ann Allergy Asthma Immunol. 2006;144:904-912 (Pubitemid 46768131)
19. Chowdhury BA, Dal Pan G. The FDA and safe use of long-Acting beta-Agonists in the treatment of asthma. N Engl J Med. 2010;362:1169-1171
20. Accolate, [Package Insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2009
21. Kelloway JS. Zafirlukast: The first leukotriene-receptor antagonist approved for the treatment of asthma. Ann Pharmacother. 1997;31:1012-1021 (Pubitemid 27390959)
22. Gamble J, Stevenson M, McClean E, et al. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2009;180:817-822
23. Singulair, [Package Insert]. Whitehouse Station, NJ: Merck and Co., Inc; 2009
24. Advair, [Package Insert]. Research Triangle Park, NC: Glaxo SmithKIine; 2010
25. Samuelsson B. Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220:568-575 (Pubitemid 13130140)
26. Folco G, Rossoni G, Buccellati C, et al. Leukotrienes in cardiovascular diseases. Am J Respir Crit Care Med. 2000; 161:S112-S116 (Pubitemid 30129427)
27. Singh RK, Gupta S, Dastidar S, et al. Cysteinyl leukotrienes and their receptors: Molecular and functional characteristics. Pharmacology. 2010;85:336-349
28. Nielsen CK, Campbell JI, Ohd JF, et al. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res. 2005;65:732-742 (Pubitemid 40220345)
29. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med. 2007;357:1841-1854
30. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399:789-793 (Pubitemid 29293175)
31. Zhu J, Qiu YS, Figueroa DJ, et al. Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa. Am J Respirat Cell Mol Biol. 2005;33:531-540 (Pubitemid 41753128)
32. Figueroa DJ, Borish L, Baramki D, et al. Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy. 2003;33:1380-1388 (Pubitemid 37289934)
33. Shirasaki H, Kanaizumi E, Watanabe K, et al. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy. 2002;32:1007-1012 (Pubitemid 34779595)
34. Corrigan C, Mallett K, Ying S, et al. Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-Tolerant chronic rhinosinusitis. J Allergy Clin Immunol. 2005;115:316-322 (Pubitemid 40215095)
35. Takasaki J, Kamohara M, Matsumoto M, et al. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun. 2000;274:316-322 (Pubitemid 30614317)
36. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000;275:30531-30536
37. FujiiM, Tanaka H, Abe S. Interferon-gamma up-regulates expression of cysteinyl leukotriene type 2 receptors on eosinophils in asthmatic patients. Chest. 2005;128: 3148-3155 (Pubitemid 41698634)
38. Wunder F, Tinel H, Kast R, et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol. 2010;160:399-409
39. Drazen JM. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy. 1997;17(1 pt 2):22S-30S. (Pubitemid 27057110)
40. Nicosia S, Capra V, Rovati GE, Leukotrienes as mediators of asthma. Pulm Pharmacol Ther. 2001;14:3-19 (Pubitemid 32158292)
41. Wang CG, Du T, Xu LJ, et al. Role of leukotriene D4 in allergen-induced increases in airway smooth muscle in the rat. Am Rev Respir Dis. 1993;148:413-417 (Pubitemid 23221587)
42. Philip G, van Adelsberg J, Loeys T, et al. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol. 2009;124:942-948. e1-e9
43. Schumock GT, Lee TA, Joo MJ, et al. Association between leukotriene-modifying agents and suicide: What is the evidence? Drug Saf. 2011;34:533-544
44. Schumock GT, Stayner LT, Valuck RJ, et al. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: A nested case-control study. J Allergy Clin Immunol. 2012;130:368-375
45. Keogh KA, Specks U. Churg-Strauss syndrome. Semin Respir Crit care Med. 2006;27:148-157
46. Lilly CM, Churg A, Lazarovich M, et al. Asthma therapies and Churg-Strauss syndrome. J Allergy Clin Immunol. 2002;109:S1-S19 (Pubitemid 34112152)
47. Wechsler ME, Wong DA, Miller MK, et al. Churgstrauss syndrome in patients treated with omalizumab. Chest. 2009;136:507-518
48. Bibby S, Healy B, Steele R, et al. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: An analysis of the FDA AERS database. Thorax. 2010;65:132-138
49. Churg A, Brallas M, Cronin SR, et al. Formes frustes of Churg-Strauss syndrome. Chest. 1995;108:320-323
50. Harrold LR, Patterson MK, Andrade SE, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmacoepidemiol Drug Saf. 2007;16:620-626 (Pubitemid 47039528)
51. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: A multicenter, randomized, doubleblind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2009;181:116-124
52. Nathani N, Little MA, Kunst H, et al. Churg-Strauss syndrome and leukotriene antagonist use: A respiratory perspective. Thorax. 2008;63:883-888
53. Hauser T, Mahr A, Metzler C, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: A case-crossover study. Thorax. 2008;63:677-682
54. Vargo DL, Y C, Lasseter K, et al. Effect of zafirlukast on prothrombin time and area under the curve of warfarin. J Clin Pharmacol. 1997;37:870. Abstract
55. Van Hecken A, Depre M, Verbesselt R, et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol. 1999;39:495-500 (Pubitemid 29356470)
56. Walsky RL, Obach RS, Gaman EA, et al. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos. 2005;33:413-418 (Pubitemid 40279942)
57. Jaakkola T, Backman JT, Neuvonen M, et al. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. Eur J Clin Pharmacol. 2006;62:503-509
58. Kim KA, Park P-W, Kim KR, et al. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans. Br J Clin Pharmacol. 2007;63:339-345
59. Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J pediatr. 2005;147:213-220 (Pubitemid 41207836)
60. Sorkness CA, Lemanske RF Jr, Mauger DT, et al. Longterm comparison of 3 controller regimens for mildmoderate persistent childhood asthma: The Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2007; 119:64-72 (Pubitemid 46043379)
61. Wang L, Hollenbeak CS, Mauger DT, et al. Costeffectiveness analysis of fluticasone versus montelukast in children with mild-To-moderate persistent asthma in the Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2011;127:161-166. 166 e1
62. Zeiger RS, Bird SR, Kaplan MS, et al. Short-Term and long-Term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: A randomized controlled trial. Am J Med. 2005;118:649-657 (Pubitemid 40732705)
63. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58:211-216 (Pubitemid 36307998)
64. Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol. 1999;103:1075-1080 (Pubitemid 29343073)
65. Ram FS, Cates CJ, Ducharme FM. Long-Acting beta2-Agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev. 2005;CD003137
66. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-Acting beta2-Agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev. 2011;CD003137
67. Fanta CH. Asthma. N Engl J Med. 2009;360:1002-1014
68. Currie GP, Lee DK, Srivastava P. Long-Acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? Chest. 2005;128:2954-2962 (Pubitemid 41507655)
69. Joos S, Miksch A, Szecsenyi J, et al. Montelukast as addon therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: A systematic review. Thorax. 2008;63:453-462 (Pubitemid 351698876)
70. Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011;364:1695-1707
71. Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: Results of an openlabel extension study evaluating long-Term safety, satisfaction, and adherence with therapy. Curr Med Res Opin. 2001;17:96-104 (Pubitemid 32964000)
72. Virchow JC, Mehta A, Ljungblad L, et al. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast in Chronic Asthma (MONICA) study. Respir Med. 2010; 104:644-651
73. Silverman RA, Nowak RM, Korenblat PE, et al. Zafirlukast treatment for acute asthma: Evaluation in a randomized, double-blind, multicenter trial. Chest. 2004; 126:1480-1489 (Pubitemid 39525020)
74. Camargo CA Jr, Smithline HA, Malice MP, et al. A randomized controlled trial of intravenous montelukast in acute asthma.AmJ Respir Crit Care Med. 2003;167:528-533
75. Camargo CA Jr, Gurner DM, Smithline HA, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol. 2010;125:374-380
76. Morris CR, Becker AB, Pinieiro A, et al. A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma. Ann Allergy Asthma Immunol. 2010;104:161-171
77. Nelson KA, Smith SR, Trinkaus K, et al. Pilot study of oral montelukast added to standard therapy for acute asthma exacerbations in children aged 6 to 14 years. Pediatr Emerg Care. 2008;24:21-27 (Pubitemid 351158763)
78. Todi VK, Lodha R, Kabra SK. Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: A randomised, doubleblind, placebo controlled trial. Arch Dis Child. 2010;95: 540-543
79. Schuh S, Willan AR, Stephens D, et al. Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial. J Pediatr. 2009;155:795-800
80. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115:233-242 (Pubitemid 40215084)
81. Virchow JC, Mehta A, Ljungblad L, et al. A subgroup analysis MONICA study: A 12-month, open-label study add-on montelukast treatment asthma patients. J Asthma. 2010;47:986-993
82. Smith CM, Christie PE, Hawksworth RJ, et al. Urinary leukotriene E4 levels after allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis. 1991; 144:1411-1413
83. Kumlin M, Dahlen B, Bjorck T, et al. Urinary excretion of leukotriene E4 and 11-dehydro-Thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis. 1992;146:96-103
84. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602-615
85. Rabinovitch N, Graber NJ, Chinchilli VM, et al. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. J Allergy Clin Immunol. 2010;126:545-551. e1-e4
86. Xolair, [Package Insert]. South San Fransisco, CA: Genentech, Inc; 2007
87. Sandstrom T. Omalizumab in the management of patients with allergic (IgE-mediated) asthma. J Asthma Allergy. 2009;2:49-62
88. Jabara HH, Ahern DJ, Vercelli D, et al. Hydrocortisone and IL-4 induce IgE isotype switching in human B cells. J Immunol. 1991;147:1557-1560
89. Djukanovic R. Effects of treatment with anti-immunoglobulin e antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004; 170:583-593
90. Hendeles L, Sorkness CA. Anti-immunoglobulin E therapy with omalizumab for asthma. Ann Pharmacother. 2007;41:1397-1410 (Pubitemid 47311360)
91. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: A systematic review. Chest. 2011; 139:28-35
92. Cox L, Lieberman P, Wallace D, et al. American Academy of allergy, asthma & Immunology/American College of allergy, asthma & immunology omalizumabassociated anaphylaxis joint task force follow-up report. J Allergy Clin Immunol. 2011;128:210-212
93. Cruz AA, Lima F, Sarinho E, et al. Safety of antiimmunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy J. 2007;37:197-207 (Pubitemid 46148277)
94. Cooper PJ, Ayre G, Martin C, et al. Geohelminth infections: A review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy. 2008;63: 409-417 (Pubitemid 351341818)
95. Fernandez CBW, Reisner C, Gupta N, et al. Clinical data do not suggest a causal relationship between omalizumab therapy and cancer. Proc Am Thorac Soc. 2005;2: A359
96. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184-190 (Pubitemid 32735398)
97. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254-261 (Pubitemid 32776398)
98. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin e antibody (Omalizumab). Pediatrics. 2001;108:e36
99. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124:1210-1216
100. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309-316 (Pubitemid 40293346)
101. Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy. 2008;63:670-684 (Pubitemid 351591863)
102. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-Tosevere allergic asthma. J Allergy Clin Immunol. 2004; 114:265-269 (Pubitemid 39119022)
103. Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model. J Allergy Clin Immunol. 2007;120:1146-1152 (Pubitemid 350029901)
104. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;CD003559
105. Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma-. Chest. 2004;125:1378-1386 (Pubitemid 38501353)
106. Cox PG, Miller J, Mitzner W, et al. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: Preliminary investigations. Eur Respir J. 2004; 24:659-663 (Pubitemid 39406141)
107. Thomson NC, Rubin AS, Niven RM, et al. Long-Term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. BMC Pulm Med. 2011;11:8
108. Pavord ID. 5-Year safety of bronchial thermoplasty demonstrated in patients with severe refractory asthma: Research in severe asthma (RISA) trial. Am J Respir Crit Care Med. 2011;183(1-meeting abstracts):A6382
109. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: A multicenter, randomized, doubleblind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181:116-124
110. Pavord ID, Cox G, Thomson NC, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med. 2007;176:1185-1191 (Pubitemid 350256471)
111. Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med. 2007;356:1327-1337 (Pubitemid 46513298)
112. Bel EH. Bronchial thermoplasty: Has the promise been met? Am J Respir Crit Care Med. 2010;181:101-102
113. Castro M, Rubin A, Laviolette M, et al. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol. 2011;107: 65-70
114. Shifren A, Chen A, Castro M. Point: Efficacy of bronchial thermoplasty for patients with severe asthma. Is there sufficient evidence? Yes. Chest. 2011;140:573-575
115. Michaud G, Ernst A. Counterpoint: Efficacy of bronchial thermoplasty for patients with severe asthma.Is There Sufficient Evidence? Not Yet. Chest. 2011;140:576-577
116. Barnes PJ. New therapies for asthma: Is there any progress? Trends Pharmacol Sci. 2010;31:335-343
117. Walsh GM. Novel cytokine-directed therapies for asthma. Discov Med. 2011;11:283-291
118. Holgate ST. Novel targets of therapy in asthma. Curr Opin Pulm Med. 2009;15:63-71
119. Paul G, Brehm J, Alcorn JF, et al. Vitamin D and asthma. Am J Respir Crit Care Med. 2011
120. Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon-gamma: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011;127:701-721. e1-e70
121. Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: A randomized, controlled trial. Am J Respir Crit Care Med. 2008;178:1002-1008
122. Dimov VV, Casale TB. Immunomodulators for asthma. Allergy Asthma Immunol Res. 2010;2:228-234
123. Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol. 2000;105(6 pt 1):1063-1070 (Pubitemid 30418781)
124. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001;107:963-970 (Pubitemid 32523334)
125. Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002;130: 93-100
126. Antoniu SA. Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. Curr Opin Investig Drugs. 2010;11:1286-1294
127. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Lancet. 2007;370:1422-1431 (Pubitemid 47576168)
128. Walsh GM. Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD. Curr Opin Investig Drugs. 2010;11:1305-1312
129. Busse WW, Ring J, Huss-Marp J, et al. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol. 2010;125:803-813
130. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356:2144-2148
131. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Am J Respir Crit Care Med. 2003;167:1655-1659 (Pubitemid 36760679)
132. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176:1062-1071 (Pubitemid 350223751)
133. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973-984
134. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985-993
135. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125-1132
136. McCallister JW. Reslizumab and eosinophilic asthma: One step closer to phenotype-directed therapy? Am J Respir Crit Care Med. 2011;184:1096-1097
137. Oh CK, Raible D, Geba GP, et al. Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma. Inflamm Allergy Drug Targets. 2011; 10:180-186
138. White B, Leon F, White W, et al. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. Clin Ther. 2009;31: 728-740
139. Parker JM, Oh CK, LaForce C, et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med. 2011;11:14
140. Caramori G, Groneberg D, Ito K, et al. New drugs targeting Th2 lymphocytes in asthma. J Occup Med Toxicol. 2008;3(SUPPL1):S6
141. Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-controlled study CRTH2 antagonist OC000459 moderate persistent asthma. Clin Exp Allergy. 2012;42:38-48
142. Razi CH, Harmanci K, Abaci A, et al. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. J Allergy Clin Immunol. 2010;126: 763-769
143. Pioglitazone, [Package Insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2007
144. Hashimoto Y, Nakahara K. Improvement of asthma after administration of pioglitazone. Diabetes Care. 2002;25:401
145. Spears M, Donnelly I, Jolly L, et al. Bronchodilatory effect of the PPAR-[gamma] agonist rosiglitazone in smokers with asthma. Clin Pharmacol Ther. 2009;86: 49-53
146. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471 (Pubitemid 46919772)
147. Karpel JP, Dworkin F, Hager D, et al. Inhaled furosemide is not effective in acute asthma. Chest. 1994;106: 1396-1400 (Pubitemid 24346098)
148. Yen Z-S, Chen S-C. Nebulised furosemide in acute adult asthma. Emerg Med J. 2005;22:654-655 (Pubitemid 41200638)
149. Ceyhan BB, Celikel T. Effect of inhaled low molecular weight heparin on methacholine-induced bronchoconstriction. Int J Clin Pharmacol Ther. 2000;38:446-451
150. Newman KB, Mason UG, Buchmeier A, et al. Failure of colchicine to reduce inhaled triamcinolone dose in patients with asthma. J Allergy Clin Immunol. 1997;99: 176-178 (Pubitemid 27091564)
151. Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev. 2001;CD002993
152. Patel K, MK, Dudney T, et al. Role of mycophenolate mofetil in steroid dependent asthma. Am J Respirat Crit Care Med. 2010;181(Suppl):A2755
153. Backer V, Hjardem E, Karlsmark T. Treatment with mycophenolat mofetil of steroid-dependent asthmaone case of severe asthma. J Allergy (Cairo). 2009;2009: 821013
154. Aaron SD, Dales RE, Pham B. Management of steroiddependent asthma with methotrexate: A meta-Analysis of randomized clinical trials. Respir Med. 1998;92: 1059-1065 (Pubitemid 28416838)
155. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev. 2000;CD000391
156. Kishiyama JL, Olson L, Gibson P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol. 1999;91:126-133 (Pubitemid 29203411)
157. Niggemann B, Leupold W, Schuster A, et al. Prospective, double-blind, placebo-controlled, multicentre study effect high-dose, intravenous immunoglobulin children adolescents severe bronchial asthma. Clin Exp Allergy. 1998;28:205-210 (Pubitemid 28137336)
158. Bernstein IL, Bernstein DI, Dubb JW, et al. A placebocontrolled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. J Allergy Clin Immunol. 1996;98:317-324 (Pubitemid 26326126)
159. Nierop G, Gijzel WP, Bel EH, et al. Auranofin in the treatment of steroid dependent asthma: A double blind study. Thorax. 1992;47:349-354
160. Berry M, Brightling C, Pavord I, et al. TNF-A in asthma. Curr Opin Pharmacol. 2007;7:279-282
161. Ying S, Robinson DS, Varney V, et al. TNF alpha mRNA expression allergic inflammation. Clin Exp Allergy. 1991; 21:745-750
162. Bradding P, Roberts JA, Britten KM, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-Alpha in normal and asthmatic airways: Evidence for the human mast cell as a source of these cytokines. Am J Respirat Cell Mol Biol. 1994;10:471-480
163. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-Alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med. 1995;152:76-80
164. van Overveld FJ, Jorens PG, Rampart M, et al. Tumour necrosis factor stimulates human skin mast cells to release histamine and tryptase. Clin Exp Allergy. 1991; 21:711-714
165. Enbrel, [Package Insert]. Thousand Oaks, CA: Immunex Corporation; 2003
166. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005;60:1012-1018 (Pubitemid 41705469)
167. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor a in refractory asthma. NEngl J Med. 2006;354:697-708 (Pubitemid 43247140)
168. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-Alpha in asthma. Am J Respir Crit Care Med. 2006; 174:753-762 (Pubitemid 44511656)
169. Remicade, [Package Insert]. Malvern, PA: Centocor, Inc; 2000
170. On Behalf of the American Thoracic Society. Retraction of four articles and abstracts. Am J Respir Crit Care Med. 2011;183:418
171. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled Study of tumor necrosis Factor-{alpha} Blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549-558
172. Matera MG, Calzetta L, Cazzola M. TNF-Alpha inhibitors in asthma and COPD: We must not throw the baby out with the bath water. Pulmonary Pharmacol Ther. 2010;23:121-128
173. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006;61:729-734 (Pubitemid 44211783)
174. Gurevich VS, Shovman O, Slutzky L, et al. Statins and autoimmune diseases. Autoimmun Rev. 2005;4:123-129 (Pubitemid 40488740)
175. Zeki AA, Franzi L, Last J, et al. Simvastatin inhibits airway hyperreactivity: Implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med. 2009; 180:731-740
176. Zocor, [Package Insert]. Northumberland, United Kingdom: Merck Sharp & Dohme, Ltd; 2008
177. Hothersall EJ, Chaudhuri R, McSharry C, et al. Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax. 2008;63:1070-1075
178. Lipitor, [Package insert]. Dubin, Ireland: Pfizer Ireland Pharmaceuticals, Inc; 2006
179. Lokhandwala T, West-Strum D, Banahan BF, et al. Do statins improve outcomes in patients with asthma on inhaled corticosteroid therapy? A retrospective cohort analysis. BMJ Open. 2012;2
180. Huang C-C, Chan W-L, Chen Y-C, et al. Statin use in patients with asthma - A nationwide population-based study. Eur J Clin Invest. 2011;41:507-512
181. Stanek E, Aubert R, Xia F, et al. Statin exposure reduces the risk of asthma-related hospitalizations and emergency room visits in asthmatic patients on inhaled corticosteroids. J Allergy Clin Immunol. 2009;123:S65
182. Bosnjak B, Stelzmueller B, Erb KJ, et al. Treatment of allergic asthma: Modulation of Th2 cells and their responses. Respir Res. 2011;12:114
183. Khoshoo V, Mohnot S, Haydel R Jr, et al. Bronchial hyperreactivity in non-Atopic children with asthma and reflux: Effect of anti-reflux treatment. Pediatr Pulmonol. 2009;44:1070-1074
184. Khoshoo V, Haydel R Jr. Effect of antireflux treatment on asthma exacerbations in nonatopic children. J Pediatr Gastroenterol Nutr. 2007;44:331-335 (Pubitemid 46673380)
185. DiMango E, Holbrook JT, Simpson E, et al. Effects of asymptomatic proximal and distal gastroesophageal reflux on asthma severity. Am J Respir Crit Care Med. 2009;180:809-816
186. Stordal K, Johannesdottir GB, Bentsen BS, et al. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease. Arch Dis Child. 2005;90:956-960 (Pubitemid 41232350)
187. Centers, W.C.f.t.A.L.A.A.C.R. Lansoprazole for children with poorly controlled asthma. JAMA. 2012;307: 373-380
188. American Lung Association Asthma Clinical Research Centre. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med. 2009;360: 1487-1499
189. Osler W, McCrae T. The Principles and Practice of Medicine; Designed for the Use of Practitioners and Students of Medicine. 8th ed. New York, NY: D. Appleton and company; 1912:1226
190. Cecil RLF, McDermott W, Wolff HG. A Textbook of Medicine. 7th ed. Philadelphia, PA: Saunders; 1947:1730
191. Beeson PB, McDermott W, Cecil RL. Textbook of Medicine. 14th ed. Philadelphia, PA: Saunders; 1975:1892
192. Combivent, [Package Insert]. Ridgefield, CT; 2008
193. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: Genotypestratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364:1505-1512 (Pubitemid 39410416)
194. Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-Adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): A genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet. 2009;374:1754-1764
195. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline update from the American College of physicians, American College of chest physicians, American Thoracic Society, and European respiratory Society. Ann Intern Med. 2011;155:179-191
196. Spiriva, [Package Insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer, Inc; 2011
197. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363:1715-1726
198. Kerstjens HA, Disse B, Schroder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial. J Allergy Clin Immunol. 2011;128:308-314
199. Denning DW, O'Driscoll BR, Hogaboam CM, et al. The link between fungi and severe asthma: A summary of the evidence. Eur Respir J. 2006;27:615-626 (Pubitemid 43372538)
200. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med. 2009;179:11-18
201. Sporanox, [Package insert]. Titusville, NJ: Janssen Pharmaceutica Products, L.P; 2001
202. Graham V, Lasserson T, Rowe BH. Antibiotics for acute asthma. Cochrane Database Syst Rev. 2001;CD002741
203. Zithromax, [Package insert]. New York, NY: Pfizer, Inc; 2010
204. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomised trial. Thorax. 2002;57: 212-216 (Pubitemid 34214405)
205. Clement A, Tamalet A, Leroux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax. 2006; 61:895-902 (Pubitemid 44570311)
206. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689-698
207. Hatipoglu U, Rubinstein I. Low-dose, long-Term macrolide therapy in asthma: An overview. Clin Mol Allergy. 2004;2:4
208. Biaxin, [Package Insert]. North Chicago, IL: Abbott Laboratories; 2011
209. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177:148-155
210. Kostadima E, Tsiodras S, Alexopoulos EI, et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J. 2004; 23:714-717 (Pubitemid 38618141)
211. Spahn JD, Fost DA, Covar R, et al. Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: Results of a pilot study. Ann Allergy Asthma Immunol. 2001;87:501-505 (Pubitemid 34001039)
212. Szefler SJ, Rose JQ, Ellis EF, et al. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol. 1980;66:447-451 (Pubitemid 11207451)
213. Evans DJ, Cullinan P, Geddes DM. Troleandomycin as an oral corticosteroid steroid sparing agent in stable asthma. Cochrane Database Syst Rev. 2001;CD002987
214. Johnston SL, Martin RJ. Chlamydophila pneumoniae and Mycoplasma pneumoniae: A role in asthma pathogenesis? Am J Respir Crit Care Med. 2005;172:1078-1089 (Pubitemid 43066642)
215. Kraft M, Cassell GH, Pak J, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: Effect of clarithromycin. Chest. 2002;121:1782-1788 (Pubitemid 34634396)
216. Black PN, Blasi F, Jenkins CR, et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med. 2001;164:536-541 (Pubitemid 32801652)
217. Sutherland ER, King TS, Icitovic N, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin immunol. 2010;126: 747-753
218. Johnston SL, Blasi F, Black PN, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med. 2006;354:1589-1600
219. Daliresp, [Package Insert]. St. Louis, MO: Forest Pharmaceuticals Inc; 2011
220. Barnes PJ. Theophylline: New perspectives for an old drug. Am J Respir Crit Care Med. 2003;167:813-818 (Pubitemid 36801766)
221. Fan Chung K. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol. 2006;533:110-117 (Pubitemid 43348344)
222. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005;365:167-175 (Pubitemid 40091808)
223. Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol. 2006;96:679-686
224. Bousquet J, Aubier M, Sastre J, et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy. 2006;61:72-78 (Pubitemid 43381194)
225. Manning CD, Burman M, Christensen SB, et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol. 1999;128:1393-1398
226. Cushley MJ, Holgate ST. Bronchodilator actions of xanthine derivatives administered by inhalation in asthma. Thorax. 1985;40:176-179 (Pubitemid 15108300)
227. Antoniu SA. New therapeutic options in the management of COPD - focus on roflumilast. Int J Chron Obstruct Pulmon Dis. 2011;6:147-155
228. Ortiz JL, Valles JM, Marti-Cabrera M, et al. Effects of selective phosphodiesterase inhibitors on platelet-Activating factor and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs. Naunyn Schmiedebergs Arch Pharmacol. 1996;353:200-206 (Pubitemid 26042731)
229. Toward TJ, Smith N, Broadley KJ. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Crit Care Med. 2004; 169:227-234 (Pubitemid 38114539)
230. Charan NB. Does sildenafil also improve breathing? Chest. 2001;120:305-306 (Pubitemid 32744895)
231. Al Qadi-Nassar B, Bichon-Laurent F, Portet K, et al. Effects of L-Arginine and phosphodiesterase-5 inhibitor, sildenafil, on inflammation and airway responsiveness of sensitized BP2 mice. Fundam Clin Pharmacol. 2007;21:611-620 (Pubitemid 350151247)
232. Chevalier E, Lagente V, Dupont M, et al. Lack of involvement of type 7 phosphodiesterase in an experimental model of asthma. Eur Respir J. 2011
233. Garbe E, LeLorier J, Boivin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-Angle glaucoma. JAMA. 1997;277:722-727 (Pubitemid 27106224)
234. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA. 1998;280:539-543 (Pubitemid 28377673)
235. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337:8-14 (Pubitemid 27290841)
236. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet. 2000;355:1399-1403 (Pubitemid 30215962)
237. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline- defined asthma control be achieved?: The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004;170:836-844 (Pubitemid 39346477)
238. Cates CJ, Lasserson TJ. Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev. 2009;CD007313
239. Cho SH. Pharmacogenomic approaches to asthma treatment. Allergy Asthma Immunol Res. 2010;2:177-182
240. Jarjour NN, Erzurum SC, Bleecker ER, et al. Severe asthma: Lessons learned from the national heart, lung, and blood institute severe asthma research program. Am J Respirat Crit Care Med. 2012;185:356-362
241. Holgate ST. Trials and tribulations in identifying new biologic treatments for asthma. Trends Immunol. 2012;33:238-246
242. Ehrs PO, Nokela M, Stallberg B, et al. Brief questionnaires for patient-reported outcomes in asthma: Validation and usefulness in a primary care setting. Chest. 2006;129:925-932
243. Carroll CL, Sekaran AK, Lerer TJ, et al. A modified pulmonary index score with predictive value for pediatric asthma exacerbations. Ann Allergy Asthma Immunol. 2005;94:355-359 (Pubitemid 40396581)